{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:19:48Z","timestamp":1769113188885,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,29]],"date-time":"2017-10-29T00:00:00Z","timestamp":1509235200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00417-017-3836-1","type":"journal-article","created":{"date-parts":[[2017,10,29]],"date-time":"2017-10-29T02:51:24Z","timestamp":1509245484000},"page":"83-89","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success"],"prefix":"10.1007","volume":"256","author":[{"given":"Rita","family":"Laiginhas","sequence":"first","affiliation":[]},{"given":"Marta In\u00eas","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Vitor","family":"Rosas","sequence":"additional","affiliation":[]},{"given":"Susana","family":"Penas","sequence":"additional","affiliation":[]},{"given":"Vitor Adriano","family":"Fernandes","sequence":"additional","affiliation":[]},{"given":"Am\u00e2ndio","family":"Rocha-Sousa","sequence":"additional","affiliation":[]},{"given":"\u00c2ngela","family":"Carneiro","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Falc\u00e3o-Reis","sequence":"additional","affiliation":[]},{"given":"Manuel Sousa","family":"Falc\u00e3o","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2017,10,29]]},"reference":[{"key":"3836_CR1","first-page":"S292","volume":"22","author":"MH Seenu","year":"2016","unstructured":"Seenu MH (2016) Current approaches to the Management of Diabetic Macular Edema. Am J Manag Care 22:S292\u2013S299","journal-title":"Am J Manag Care"},{"key":"3836_CR2","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"JA Wells","year":"2015","unstructured":"Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372:1193\u20131203. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1414264","journal-title":"N Engl J Med"},{"key":"3836_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.4239\/wjd.v7.i16.333","volume":"7","author":"MW Stewart","year":"2016","unstructured":"Stewart MW (2016) Treatment of diabetic retinopathy: recent advances and unresolved challenges. World J Diabetes 7:333\u2013341. \nhttps:\/\/doi.org\/10.4239\/wjd.v7.i16.333","journal-title":"World J Diabetes"},{"key":"3836_CR4","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaophthalmol.2016.1669","volume":"134","author":"EL Ross","year":"2016","unstructured":"Ross EL, Hutton DW, Stein JD, Bressler NM, Jampol LM, Glassman AR (2016) Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial. JAMA Ophthalmol 134:888\u2013896. \nhttps:\/\/doi.org\/10.1001\/jamaophthalmol.2016.1669","journal-title":"JAMA Ophthalmol"},{"key":"3836_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/jamaophthalmol.2015.4110","volume":"134","author":"JS Heier","year":"2016","unstructured":"Heier JS, Bressler NM, Avery RL, Bakri SJ, Boyer DS, Brown DM, Dugel PU, Freund KB, Glassman AR, Kim JE, Martin DF, Pollack JS, Regillo CD, Rosenfeld PJ, Schachat AP, Wells JA 3rd (2016) Comparison of Aflibercept, Bevacizumab, and Ranibizumab for treatment of diabetic macular edema: extrapolation of data to clinical practice. JAMA Ophthalmol 134:95\u201399. \nhttps:\/\/doi.org\/10.1001\/jamaophthalmol.2015.4110","journal-title":"JAMA Ophthalmol"},{"key":"3836_CR6","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.ophtha.2010.03.045","volume":"117","author":"M Michaelides","year":"2010","unstructured":"Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, Boos CJ, Xing W, Egan C, Peto T, Bunce C, Leslie RD, Hykin PG (2010) A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 117:1078\u20131086.e1072. \nhttps:\/\/doi.org\/10.1016\/j.ophtha.2010.03.045","journal-title":"Ophthalmology"},{"key":"3836_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1517\/14712598.2016.1131265","volume":"16","author":"RM Hussain","year":"2016","unstructured":"Hussain RM, Ciulla TA (2016) Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy. Expert Opin Biol Ther 16:365\u2013374. \nhttps:\/\/doi.org\/10.1517\/14712598.2016.1131265","journal-title":"Expert Opin Biol Ther"},{"key":"3836_CR8","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ophtha.2015.11.008","volume":"123","author":"DV Do","year":"2016","unstructured":"Do DV, Nguyen QD, Vitti R, Berliner AJ, Gibson A, Saroj N, Soo Y, Boyer DS (2016) Intravitreal Aflibercept injection in diabetic macular edema patients with and without prior anti-vascular endothelial growth factor treatment: outcomes from the phase 3 program. Ophthalmology 123:850\u2013857. \nhttps:\/\/doi.org\/10.1016\/j.ophtha.2015.11.008","journal-title":"Ophthalmology"},{"key":"3836_CR9","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/eye.2014.64","volume":"28","author":"C Ehlken","year":"2014","unstructured":"Ehlken C, Jungmann S, Bohringer D, Agostini HT, Junker B, Pielen A (2014) Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD. Eye (London, England) 28:538\u2013545. \nhttps:\/\/doi.org\/10.1038\/eye.2014.64","journal-title":"Eye (London, England)"},{"key":"3836_CR10","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2147\/opth.s81523","volume":"9","author":"LS Lim","year":"2015","unstructured":"Lim LS, Ng WY, Mathur R, Wong D, Wong EY, Yeo I, Cheung CM, Lee SY, Wong TY, Papakostas TD, Kim LA (2015) Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab. Clin Ophthalmol (Auckland, NZ) 9:1715\u20131718. \nhttps:\/\/doi.org\/10.2147\/opth.s81523","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"key":"3836_CR11","doi-asserted-by":"publisher","unstructured":"Bahrami B, Hong T, Zhu M, Schlub TE, Chang A (2017) Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Graefe\u2019s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle. Ophthalmologie. \nhttps:\/\/doi.org\/10.1007\/s00417-017-3624-y","DOI":"10.1007\/s00417-017-3624-y"},{"key":"3836_CR12","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3928\/23258160-20170301-06","volume":"48","author":"M Ashraf","year":"2017","unstructured":"Ashraf M, Souka AA, ElKayal H (2017) Short-term effects of early switching to Ranibizumab or Aflibercept in diabetic macular edema cases with non-response to Bevacizumab. Ophthalmic Surg, Lasers Imaging Retin 48:230\u2013236. \nhttps:\/\/doi.org\/10.3928\/23258160-20170301-06","journal-title":"Ophthalmic Surg, Lasers Imaging Retin"},{"key":"3836_CR13","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3928\/23258160-20160901-06","volume":"47","author":"CP Shah","year":"2016","unstructured":"Shah CP, Heier JS (2016) Aflibercept for diabetic macular edema in eyes previously treated with Ranibizumab and\/or Bevacizumab may further improve macular thickness. Ophthalmic Surg, Lasers Imaging Retin 47:836\u2013839. \nhttps:\/\/doi.org\/10.3928\/23258160-20160901-06","journal-title":"Ophthalmic Surg, Lasers Imaging Retin"},{"key":"3836_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ajo.2015.12.030","volume":"164","author":"E Rahimy","year":"2016","unstructured":"Rahimy E, Shahlaee A, Khan MA, Ying GS, Maguire JI, Ho AC, Regillo CD, Hsu J (2016) Conversion to Aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema. Am J Ophthalmol 164:118\u2013127.e112. \nhttps:\/\/doi.org\/10.1016\/j.ajo.2015.12.030","journal-title":"Am J Ophthalmol"},{"key":"3836_CR15","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3928\/23258160-20151008-08","volume":"46","author":"E Wood","year":"2015","unstructured":"Wood E, Karth P, Moshfeghi D, Leng T (2015) Short-term outcomes of Aflibercept therapy for diabetic macular edema in patients with incomplete response to Ranibizumab and\/or Bevacizumab. Ophthalmic Surg, Lasers Imaging Retin 46:950\u2013954","journal-title":"Ophthalmic Surg, Lasers Imaging Retin"},{"key":"3836_CR16","doi-asserted-by":"publisher","unstructured":"Ashraf M, Souka A, Adelman R, Forster SH (2016) Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. Eye (London, England). \nhttps:\/\/doi.org\/10.1038\/eye.2016.174","DOI":"10.1038\/eye.2016.174"},{"key":"3836_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000444103","volume":"235","author":"R Ehrlich","year":"2016","unstructured":"Ehrlich R, Dan I, Deitch I, Axer-Siegel R, Mimouni K (2016) The effectiveness of Intravitreal Ranibizumab in patients with diabetic macular edema who have failed to respond to Intravitreal Bevacizumab. Ophthalmologica J Int d\u2019ophtalmologie Int J Ophthalmol Zeitschrift fur Augenheilkunde 235:133\u2013136. \nhttps:\/\/doi.org\/10.1159\/000444103","journal-title":"Ophthalmologica J Int d\u2019ophtalmologie Int J Ophthalmol Zeitschrift fur Augenheilkunde"},{"key":"3836_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000375230","volume":"6","author":"J Hanhart","year":"2015","unstructured":"Hanhart J, Chowers I (2015) Evaluation of the response to Ranibizumab therapy following Bevacizumab treatment failure in eyes with diabetic macular edema. Case Rep Ophthalmol 6:44\u201350. \nhttps:\/\/doi.org\/10.1159\/000375230","journal-title":"Case Rep Ophthalmol"},{"key":"3836_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1136\/bjophthalmol-2013-303954","volume":"98","author":"PS Muether","year":"2014","unstructured":"Muether PS, Droege KM, Fauser S (2014) Vascular endothelial growth factor suppression times in patients with diabetic macular oedema treated with ranibizumab. Br J Ophthalmol 98:179\u2013181. \nhttps:\/\/doi.org\/10.1136\/bjophthalmol-2013-303954","journal-title":"Br J Ophthalmol"},{"key":"3836_CR20","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ophtha.2016.02.007","volume":"123","author":"DJ Pieramici","year":"2016","unstructured":"Pieramici DJ, Wang PW, Ding B, Gune S (2016) Visual and anatomic outcomes in patients with diabetic macular edema with limited initial anatomic response to Ranibizumab in RIDE and RISE. Ophthalmology 123:1345\u20131350. \nhttps:\/\/doi.org\/10.1016\/j.ophtha.2016.02.007","journal-title":"Ophthalmology"},{"key":"3836_CR21","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1001\/archophthalmol.2012.1107","volume":"130","author":"SB Bressler","year":"2012","unstructured":"Bressler SB, Qin H, Beck RW, Chalam KV, Kim JE, Melia M, Wells JA 3rd (2012) Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol (Chicago, Ill : 1960) 130:1153\u20131161. \nhttps:\/\/doi.org\/10.1001\/archophthalmol.2012.1107","journal-title":"Arch Ophthalmol (Chicago, Ill : 1960)"},{"key":"3836_CR22","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1136\/bjophthalmol-2013-303168","volume":"97","author":"S Sivaprasad","year":"2013","unstructured":"Sivaprasad S, Crosby-Nwaobi R, Heng LZ, Peto T, Michaelides M, Hykin P (2013) Injection frequency and response to bevacizumab monotherapy for diabetic macular oedema (BOLT report 5). Br J Ophthalmol 97:1177\u20131180. \nhttps:\/\/doi.org\/10.1136\/bjophthalmol-2013-303168","journal-title":"Br J Ophthalmol"},{"key":"3836_CR23","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.2147\/opth.s110789","volume":"10","author":"BJ Thomas","year":"2016","unstructured":"Thomas BJ, Yonekawa Y, Wolfe JD, Hassan TS (2016) Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema. Clin Ophthalmol (Auckland, NZ) 10:1679\u20131684. \nhttps:\/\/doi.org\/10.2147\/opth.s110789","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"key":"3836_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3109\/02713683.2014.1002048","volume":"41","author":"Y Totan","year":"2016","unstructured":"Totan Y, Guler E, Guragac FB (2016) Dexamethasone Intravitreal implant for chronic diabetic macular edema resistant to Intravitreal Bevacizumab treatment. Curr Eye Res 41:107\u2013113. \nhttps:\/\/doi.org\/10.3109\/02713683.2014.1002048","journal-title":"Curr Eye Res"},{"key":"3836_CR25","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1167\/iovs.12-10757","volume":"54","author":"P Mitchell","year":"2013","unstructured":"Mitchell P, Chong V (2013) Baseline predictors of 3-year responses to ranibizumab and laser photocoagulation therapy in patients with visual impairment due to diabetic macular edema (DME): the RESTORE study. Invest Ophthalmol Vis Sci 54:2373\u20132373","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3836_CR26","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.ophtha.2015.04.029","volume":"122","author":"AS Bansal","year":"2015","unstructured":"Bansal AS, Khurana RN, Wieland MR, Wang PW, Van Everen SA, Tuomi L (2015) Influence of Glycosylated hemoglobin on the efficacy of Ranibizumab for diabetic macular edema: a post hoc analysis of the RIDE\/RISE trials. Ophthalmology 122:1573\u20131579. \nhttps:\/\/doi.org\/10.1016\/j.ophtha.2015.04.029","journal-title":"Ophthalmology"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-017-3836-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-017-3836-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-017-3836-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T17:43:10Z","timestamp":1514828590000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-017-3836-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,29]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["3836"],"URL":"https:\/\/doi.org\/10.1007\/s00417-017-3836-1","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,29]]}}}